title: Complete regression of cutaneous lesions of refractory Ph+ ALL after 4 weeks of treatment with BMS-354825.
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Abruzzese
authors.forename: Giovanni
authors.initials: G
authors.lastname: Del Poeta
authors.forename: Rosanna
authors.initials: R
authors.lastname: Barbato
authors.forename: Stefano
authors.initials: S
authors.lastname: Fratoni
authors.forename: Malgorzata M
authors.initials: MM
authors.lastname: Trawinska
authors.forename: Daniela
authors.initials: D
authors.lastname: Zangrilli
authors.forename: Angela M
authors.initials: AM
authors.lastname: Coletta
authors.forename: Ivona M
authors.initials: IM
authors.lastname: Patroi
authors.forename: Francesca
authors.initials: F
authors.lastname: Francesconi
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Santeusanio
authors.forename: Paolo
authors.initials: P
authors.lastname: De Fabritiis
authors.forename: Sergio
authors.initials: S
authors.lastname: Amadori
mesh_terms: D000368:Aged; D000069439:Dasatinib; D006801:Humans; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000473:pathology; D011743:Pyrimidines / Q000627:therapeutic use*; D012074:Remission Induction / Q000379:methods; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013844:Thiazoles / Q000627:therapeutic use*
chemical_list: D011743:Pyrimidines; D013844:Thiazoles; D000069439:Dasatinib